RxDoctor Payments Data

Arlene Bravo, MD

General Practice · Temecula, CANPI 1528488350

Payments from drug & device makers

$1,098in general payments, 2019–2025

Across 37 payments — averaging $29.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$352
  • GSK$176
  • Amgen$175
  • Gilead$166
  • Boehringer Ingelheim$161
  • Pfizer$31
  • plus $38 from 2 others

What the payments were for

  • Food & beverage$1,098100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie14$352
GSK4$176
Amgen(2 entities)10$175
Gilead2$166
Boehringer Ingelheim3$161
Pfizer2$31
Johnson & Johnson1$24
UCB, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,098 in reported general payments places this provider in the 80th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$118,167
Medicare patients
213
Services billed
1,987

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab38$276,473
RinvoqUpadacitinib13$131,837
Enbrel SureclickEtanercept14$103,622
ProliaDenosumab12$21,095
Hydroxychloroquine Sulfate122$6,356
MethotrexateMethotrexate Sodium125$4,705
Cevimeline Hcl14$3,480
Leflunomide36$3,354
Mycophenolate Mofetil31$2,398
Colchicine14$1,225
Sulfasalazine DrSulfasalazine22$946
Prednisone123$748
Folic Acid50$412
Alendronate Sodium41$266
Allopurinol38$220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$352$131,83713 claims
AmgenProlia$175$21,09512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 12,963 general practice providers in California.

Other general practice in Temecula

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →